Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method

Fig. 2

Schematic of recruitment of patients in STARPAC, 3 + 3 and TITE-CRM designs of a hypothetical scenario where the true toxicity is T1, recruitment rate is R1 and DLT timings are DT4. Missed patients are with dashed boxes, recruited patients are with solid boxes and patients with DLT (which may happen anytime between days 7 to 21 as for DT4) are shown in grey boxes

Back to article page